Alector, Inc. Q2 FY2024 earnings call

Key initiatives in the first half of 2024 included advancing the AL002 Phase 2 trial INVOKE-2 expected in Q4 2024, with AL002 being a novel TREM2 agonist for neurodegenerative diseases. Latozinemab received breakthrough therapy designation for FTD with GRN mutations, and there's clarity on biomarkers for regulatory submission. Enrollment continues in the PROGRESS-AD trial for AL101. Alector introduced the Alector Brain Carrier (ABC) platform, a blood-brain barrier technology for enhanced drug delivery to the CNS using targets like TfR and CD98 heavy chain. Later-stage clinical programs for AL002 and latozinemab were discussed, including trial designs and biomarker assessments.

No detailed product segment financial performance with revenue contribution % provided in the transcript.

Ended Q2 2024 with $503.3 million in cash, cash runway through 2026. Collaboration revenue guidance $60-70 million, R&D guidance $210-220 million, G&A guidance $60-70 million. Runway extends through 2026, covering key milestones like AL002 INVOKE-2 data readout and INFRONT-3 Phase 3 data readout.

Potential risks include clinical trial outcomes not meeting expectations, safety concerns with new technologies like ABC, and regulatory uncertainties in obtaining approvals for therapies. There's also the risk of ARIA-like imaging abnormalities in trials, though efforts are being made to mitigate them.

Q: On TREM2, what proportion of data from participants out to 48 weeks and 96 weeks and somewhere in between expected in upcoming readout? And on latozinemab, what does it mean that FDA would consider plasma and CSF PGRN as confirmatory?

A: Gary Romano said all completers (around 250) will complete 48 weeks of treatment, about half 72 weeks, and a third 96 weeks. For latozinemab, FDA considers plasma and CSF PGRN as confirmatory evidence supplementing potential clinical effects, with biomarkers like GFAP and NfL as supportive evidence.

Q: How should we be thinking about patients enrolling in a long-term extension study for INVOKE-2 in terms of tolerability and efficacy?

A: Gary Romano said up to 95% of eligible patients enrolled, LTE remains blinded, collecting meaningful data on biomarkers and safety. No significant safety signals beyond ARIA-like observations and small infusion reactions.

Q: On TREM2, what to expect for first data release next quarter? What's the bar for moving program forward?

A: Gary Romano said press release will include primary clinical outcomes, safety, and relevant biomarkers. Bar is showing combination of clinical, functional, and biomarker readouts indicating slowing of disease progression.

Q: On progranulin program, have you seen or going to update on MRI signal characteristic of ARIA?

A: Gary Romano said they have MRI surveillance in the progranulin program, haven't seen such signals yet, early days, but biological activity would be encouraging if seen.

Q: On Type B meeting and AbbVie's decision process, how viewed?

A: Gary Romano said encouraged by FDA feedback on biomarkers for latozinemab, committed to full approval. AbbVie's A-beta program deprioritization not seen as direct read-through to AL002.

Q: On TREM2 and progranulin program biomarkers, any takeaway on FDA openness?

A: Gary Romano said encouraged by regulatory flexibility in rare diseases, but still confident in full approval via traditional outcomes, with backup plan using biomarkers if needed.

Q: On cash runway and ABC platform activities, details?

A: Marc Grasso said cash runway through 2026, strong position. ABC platform programs will be updated as they progress, with INDs expected for relevant programs.